Cargando…
LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for symptomatic patients with COPD, either as initial/first-line treatment or for second-line/treatment escalation in patients who experience persistent symptoms or exacerbations on monotherapy. The Global Initiative...
Autores principales: | Miravitlles, Marc, Kawayama, Tomotaka, Dreher, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692772/ https://www.ncbi.nlm.nih.gov/pubmed/36431099 http://dx.doi.org/10.3390/jcm11226623 |
Ejemplares similares
-
Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2021) -
Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020) -
Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018) -
Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019) -
EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)